Top

Published in:

01-06-2011

Adipose Tissue Dysfunction in Polycystic Ovary Syndrome

Authors: Jennifer Villa, Richard E. Pratley

Published in: Current Diabetes Reports | Issue 3/2011

Abstract

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder among premenopausal women. In addition to infertility, PCOS is associated with insulin resistance, features of the metabolic syndrome, and an increased risk for diabetes. Similar to individuals with metabolic syndrome, many women with PCOS manifest abdominal obesity, suggesting adipose tissue dysfunction. The adipose tissue of women with PCOS is characterized by hypertrophic adipocytes and impairments in lipolysis and insulin action. The expression and secretion of a wide variety of adipokines implicated in insulin resistance, including adiponectin and others, are also altered in PCOS. Collectively, the available data indicate that adipose tissue dysfunction plays a central role in the metabolic abnormalities observed in PCOS. Whether these abnormalities are primary or secondary to hyperandrogenism or other abnormalities in PCOS is not yet known.

• March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010, 25:544–551. This study compares the prevalence of PCOS using various diagnostic criteria and indicates that PCOS may be much more prevalent than commonly appreciated. PubMedCrossRef

The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.CrossRef

Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med. 2006;12(7):324–32.PubMedCrossRef

Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007;18(7):280–5.PubMedCrossRef

Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048–58.PubMedCrossRef

• Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010, 16(4):347–63. This study highlights the markedly increased risk for diabetes among women with PCOS. PubMedCrossRef

Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med. 2010;27(5):498–515.PubMedCrossRef

Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166(19):2081–6.PubMedCrossRef

Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–9.PubMedCrossRef

10.

Escobar-Morreale H, San Milla J, Abdominal adiposity and the polycystic ovary syndrome TRENDS in Endocrinology and Metabolism Vol.18 No.7

11.

Albu JB, Kovera AJ, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese non-diabetic premenopausal women. Diabetes. 1997;46:456–62.PubMedCrossRef

12.

Marsden P, Murdoch A, Taylor R. Tissue insulin sensitivity and body weight in polycystic ovary syndrome. Clin Endocrinol. 2001;55:191–9.CrossRef

13.

•• Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische A, et al. Adipose Tissue Has Aberrant Morphology and Function in PCOS: Enlarged Adipocytes and Low Serum Adiponectin, But Not Circulating Sex Steroids, Are Strongly Associated with Insulin Resistance. J. Clin. Endocrinol. Metab. 2011, 96:E304-E311. This study comprehensively examines adipose tissue morphology and function in women with PCOS. PubMedCrossRef

14.

Carmina E, Bucchieri S, Esposito A, Del Puente A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab. 2007;92:E2500–5.CrossRef

15.

Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5(1):70–5.PubMedCrossRef

16.

Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obes Rev. 2001;2(4):239–54.PubMedCrossRef

17.

Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.PubMed

18.

Kershaw EE. Flier JS Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.PubMedCrossRef

19.

Salans LB, Cushman SW, Weismann RE. Studies of human adipose tissue. Adipose cell size and number in nonobese and obese patients. J Clin Invest. 1973;52:929–41.PubMedCrossRef

20.

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia. 2000;43:1498–506.PubMedCrossRef

21.

Leonhardt W, Hanefeld M, Schneider H, Haller H. Human adipocyte volumes: maximum size, and correlation to weight index in maturity onset-diabetes. Diabetologia. 1972;8:287–91.PubMedCrossRef

22.

Faulds G, Rydén M, Ek I, Wahrenberg H, Arner P. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab. 2003;88(5):2269–73.PubMedCrossRef

23.

Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? J Clin Endocrinol Metab. 1997;82:1147–53.PubMedCrossRef

24.

Ek I, Arner P, Ryde M, Holm C, Thorne A, Hoffstedt J, et al. A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes. 2002;51:484–92.PubMedCrossRef

25.

Seow KM, Tsai YL, Hwang JL, Hsu WY, Ho LT, Juan CC. Omental adipose tissue overexpression of fatty acid transporter CD36 and decreased expression of hormone-sensitive lipase in insulin-resistant women with polycystic ovary syndrome. Hum Reprod. 2009;24(8):1982–8.PubMedCrossRef

26.

Dicker A, Ryden M, Nashund E, Muehlen IE, Wiren M, Lafontan M, et al. Effect of testosterone on lipolysis in human pre-adipocytes from different fat depots. Diabetologia. 2004;47:420–8.PubMedCrossRef

27.

Rosenbaum D, Haber RS, Dunaif A. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol. 1993;264:E197–202.PubMed

28.

Chang W, Goodarzi M, Williams H, Magoffin D, Pall M, Azziz R. Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. Fertil Steril. 2008;90(6):2291–7.PubMedCrossRef

29.

Corbould A, Dunaif A. The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metab Clin Exp. 2007;56:716–22.PubMed

30.

Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol. 2007;192:585–94.PubMedCrossRef

31.

Danforth Jr E. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000;26(1):13.PubMedCrossRef

32.

Permana PA, Nair S, Lee YH, Luczy-Bachman G, Vozarova De Courten B, Tataranni PA. Subcutaneous abdominal preadipocyte differentiation in vitro inversely correlates with central obesity. Am J Physiol Endocrinol Metab. 2004;286(6):E958–62.PubMedCrossRef

33.

Yang X, Jansson PA, Nagaev I, Jack MM, Carvalho E, Sunnerhagen KS, et al. Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun. 2004;317(4):1045–51.PubMedCrossRef

34.

Corton M, Botella-Carretero J, Bengurıa A, Villuendas G, Zaballos A, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:328–37.PubMedCrossRef

35.

Gupta V, Bhasin S, Guo W, Singh R, Miki R, Chauhan P, et al. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol. 2008;296(1–2):32–40.PubMedCrossRef

36.

Roland AV, Nunemaker CS, Keller SR, Moenter SM. Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol. 2010;207(2):213–23.PubMedCrossRef

37.

Lee YH, Nair S, Rousseau E, Allison DB, Page GP, Tataranni PA, et al. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia. 2005;48(9):1776–83.PubMedCrossRef

38.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.PubMedCrossRef

39.

Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and obRNA in obese and weight-reduced subjects. Nat Med. 1995;1:1155–61.PubMedCrossRef

40.

Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82(6):1687–91.PubMedCrossRef

41.

• Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo R. Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. Fertility and Sterility 2009, 91(4) supplement: 1332–1335. In this study, differences in several adipokines were demonstrated in ovulatory and anovulatory women with PCOS. PubMedCrossRef

42.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:E1930–5.CrossRef

43.

O’Connor A, Phelan N, Kyaw T, Boran G, Gibney J, Roche HM. High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95:1378–85.PubMedCrossRef

44.

• Toulis KA, Goulis DG, Farmakiotis D, Georgopolous NA, Katsikis I, Tarlatzis BC, Papadimas I, Panidis D. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Human Reproduction Update 2009; 15 (3): 297–307. This systematic review documents the low levels of adiponectin observed in women with PCOS. PubMedCrossRef

45.

Murat Y, Bukan N, Demirci H, Ozturk C, Kan E, Ayvaz G, et al. Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2009;25(4):246–52.CrossRef

46.

Mlinar B, Pfeifer M, Vrtachnik-Bokal E, Jensterle M, Marc J. Decreased lipin 1β expression in visceral adipose tissue is associated with insulin resistance in polycystic ovary syndrome. Eur J Endocrinol. 2008;159:833–9.PubMedCrossRef

47.

Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15(8):914–20.PubMedCrossRef

Title: Adipose Tissue Dysfunction in Polycystic Ovary Syndrome
Authors: Jennifer Villa
Richard E. Pratley
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 3/2011
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-011-0189-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Adipose Tissue Dysfunction in Polycystic Ovary Syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Perivascular Adipose Tissue and Its Role in Type 2 Diabetes and Cardiovascular Disease

Alternative and Complementary Treatments for Metabolic Syndrome

Human Vascular Endothelial Cells: A Model System for Studying Vascular Inflammation in Diabetes and Atherosclerosis

Bile Acid Metabolism and the Pathogenesis of Type 2 Diabetes

Why Does NAFLD Predict Type 2 Diabetes?

Cardiovascular Function/Dysfunction in Adolescents with Type 1 Diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page